Kinesis and Trajan are pleased to announce Kinesis as an approved distribution partner for the SGE Analytical Science range of chromatography consumables in the US.
SGE is a Trajan brand, established in 1960 and integrated into Trajan in 2013. The SGE brand is well known for its diamond syringe quality and is the global market leader in niche areas such as autosampler syringes and GC inlet liners.
Trajan’s focus is on developing and commercializing technologies that enable analytical systems to be more selective, sensitive and specific for biological, environmental or food related measurements especially those that can lead to portability, miniaturization and affordability.
Chief Executive Officer of Trajan, Stephen Tomisich said, “Thinking on both a global and local scale is critical for us. We identify key partners around the world to help us deliver a great local customer experience. The individuals that ultimately use our products are front of mind.”
Kinesis will provide a local service in the US, offering technical support and application expertise. This agreement extends the SGE product distribution by Kinesis, with partnerships already in place with its entities in the UK, Australia and India.
“By expanding Trajan’s distribution and customer support capacity through Kinesis in the US, it enables us to focus on developing innovative technologies that could make a positive impact on human wellbeing,” said Mr Tomisich.
Senior Vice President of Operations, Americas, Mr Glenn Clivaz agreed, “I look forward to strong growth in the US, working closely with Kinesis for their scientific expertise to support our end-customers using SGE products.”
“With the launch of new products at Pittcon 2015, we are keen to see Kinesis facilitating the adoption of these latest technologies in laboratories across the US,” said Mr Clivaz.
Kinesis is a leading international supplier of chromatography, liquid handling, sample storage and medicinal chemistry consumables and equipment. The ability to work directly with leading manufacturers and having the technical knowledge to support or clients ensures that our customers never have to compromise on quality, support or service.
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.